Cargando…

Current status and advances of immunotherapy in nasopharyngeal carcinoma

The general immune landscape of nasopharyngeal carcinoma (NPC) renders immunotherapy suitable for patients with NPC. Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refrac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jian-Ying, Wei, Xiao-Li, Wang, Yi-Qin, Wang, Feng-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083041/ https://www.ncbi.nlm.nih.gov/pubmed/35547095 http://dx.doi.org/10.1177/17588359221096214

Ejemplares similares

Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
por: Huang, Huageng, et al.
Publicado: (2023)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
por: Xu, Yuexin, et al.
Publicado: (2021)

Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma
por: Ghali, Fady, et al.
Publicado: (2019)

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options
por: Jiromaru, Rina, et al.
Publicado: (2022)

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)

Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy
por: Xu, Jian-Ying, et al.
Publicado: (2022)

Current Status and Future Perspectives about Molecular Biomarkers of Nasopharyngeal Carcinoma
por: Siak, Pui Yan, et al.
Publicado: (2021)

Current Management Strategy of Nasopharyngeal Carcinoma
por: Wei, William I., et al.
Publicado: (2010)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
por: Lu, Zhihao, et al.
Publicado: (2020)

Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis
por: Xiao, Lifeng, et al.
Publicado: (2021)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma
por: Zhu, Qian‐Ying, et al.
Publicado: (2021)

Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives
por: Poh, Sharon Shuxian, et al.
Publicado: (2021)

Current status and progress in immunotherapy for malignant pleural mesothelioma
por: Sun, Boyang, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
por: Xie, Yingjun, et al.
Publicado: (2018)

Current Radiotherapy Considerations for Nasopharyngeal Carcinoma †
por: Ng, Wai Tong, et al.
Publicado: (2022)

Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022)

The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives
por: Walsh, Robert J., et al.
Publicado: (2021)

Current status of cancer immunotherapy
por: Kono, K
Publicado: (2014)

Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma
por: Shengjun, Wang, et al.
Publicado: (2012)

Role of Muscle Mass and Nutritional Assessment Tools in Evaluating the Nutritional Status of Patients With Locally Advanced Nasopharyngeal Carcinoma
por: Pan, Xi, et al.
Publicado: (2021)

Recent advances in the management of nasopharyngeal carcinoma
por: Lam, W. K. Jacky, et al.
Publicado: (2018)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019)

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
por: Pang, Zhi, et al.
Publicado: (2023)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
por: Yan, Zhi-Ling, et al.
Publicado: (2022)

Current and emerging treatment options for nasopharyngeal carcinoma
por: Spratt, Daniel E, et al.
Publicado: (2012)

Management of recurrent nasopharyngeal carcinoma: current perspectives
por: Perri, F, et al.
Publicado: (2019)

Immunotherapy in the management of melanoma: current status
por: Alston, Dylan, et al.
Publicado: (2013)

Immunotherapy for advanced or recurrent hepatocellular carcinoma
por: Luo, Ying-Zhe, et al.
Publicado: (2023)

Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma
por: Jian, Yuli, et al.
Publicado: (2021)

Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses
por: Chen, Yu-Pei, et al.
Publicado: (2021)

The Current Role of Adjuvant Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma
por: Su, Lin, et al.
Publicado: (2021)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status
por: Peng, Hao, et al.
Publicado: (2016)

Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma: Implications for Tumor Immunotherapy
por: Li, Jiang, et al.
Publicado: (2007)

Current Landscape of Immunotherapy for Advanced Sarcoma
por: Albarrán, Víctor, et al.
Publicado: (2023)

Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma
por: Yin, Li, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ki5gtor6afmjhpiqd241tcseap